Announcements

Ian Krop, MD, PhD, Appointed Chief Clinical Research Officer
We are pleased to announce the appointment of Ian E. Krop, MD, PhD, as Chief Clinical Research Officer, Associate Cancer Center Director for Clinical Research, and Director of the Yale Cancer Center Clinical Trials Office. Dr. Krop will join Yale Cancer Center and Smilow Cancer Hospital on March 1, 2022, to work with our leadership team, to build on the strengths of our clinical research program and lead our staff and new recruits to advance the Clinical Trials Office. Together, we will build and support an internationally recognized clinical research program that will focus on scientific excellence, training the next generation of clinical researchers, and promoting the highest quality clinical and translational investigation.

An international leader in the clinical care of patients with breast cancer, Dr. Krop will join Yale from Dana-Farber Cancer Institute where he is the Associate Chief of the Division of Breast Oncology and an Associate Professor of Medicine at Harvard Medical School. Nationally, he serves as Chief Scientific Officer for the Translational Breast Cancer Research Consortium and the Co-Vice Chair for Correlative Science for the Alliance for Clinical Trials in Oncology. His research efforts have advanced the field through clinical trials that define the next generation of therapies for patients. Dr. Krop serves as a member of the NCI Breast Cancer Steering Committee and the Data Monitoring Committee for ECOG/ACRIN. He also serves on the Data and Safety Monitoring Boards for multiple phase III trials.

In his new role, Dr. Krop will have broad oversight of clinical research efforts at Yale Cancer Center and Smilow Cancer Hospital. His experience, skill set, and dedication to cancer research as well as his positive approach will allow him to influence both the quality of clinical trials and our associated

News Center

Talk between Immune Cells could Lead to New Cancer Vaccine

Read More
operations. He will partner with Alyssa Gateman, Interim Administrative Director of the Clinical Trials Office, and Neal Fischbach, MD, Stephanie Halene, MD, PhD, and Stacey Stein, MD, Assistant Medical Directors for the Clinical Trials Office. Roy Decker, MD, PhD, will continue to advise our clinical research team as Special Advisor to the Clinical Trials Office and will work closely with the team. Dr. Krop will collaborate with our Associate Cancer Center Directors, Research Program Leaders, and DART leadership to ensure clinical research is seamless across Yale Cancer Center and the Smilow Cancer Hospital Network.

Yale Cancer Center Faculty Appointed to Endowed Professorships
Four Yale Cancer Center faculty have been appointed to endowed professorships by the Yale University Corporation this month. Congratulations to Ranjit Bindra, MD, PhD, Stephanie Halene, MD, PhD, Suchitra Krishnan-Sarin, PhD, and David Rimm, MD, PhD.

Ranjit S. Bindra, MD, PhD
Scientific Director of the Chênevert Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center, was appointed the Harvey and Kate Cushing Professor of Therapeutic Radiology. Dr. Bindra received his undergraduate degree in molecular biophysics and biochemistry from Yale College in 1998, and both his MD and PhD from the Yale School of Medicine in 2007. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan Kettering Cancer Center in 2012, after which he was recruited to join the faculty of the Department of Therapeutic Radiology at Yale School of Medicine.

Dr. Bindra’s research program uses cutting edge technology to identify DNA repair and metabolic defects in tumors that can be exploited for therapeutic interventions across a range of cancers. His research has been published in top tier journals, including Nature, Nature Communications, and Science Translational Medicine, and has received international attention due to its major implications for the treatment of a variety of cancers. Dr. Bindra is now translating this work directly into patients in multiple clinical trials.

As a biotech entrepreneur, Dr. Bindra has founded several companies based on work from his lab and collaborators at Yale, including Cybrexa Therapeutics, Athena Therapeutics, Aztek Bio, and B3 Therapeutics.

Stephanie Halene, MD, PhD, Chief of Hematology, was appointed the Arthur H. and Isabel Bunker Associate Professor of Medicine (Hematology). Dr. Halene received her MD and PhD at Eberhard-Karls-Universität Tübingen in Germany and her postdoctoral research training at Dana-Farber Cancer Institute and St. Jude Children’s Research Hospital. Dr. Halene joined the faculty at Yale in 2009. Her research has been published in top tier journals, including Nature, Nature Medicine, and Blood. Currently, her research program focuses on developing therapeutics for cancer patients with blood malignancies. Dr. Halene has also served on the editorial board and as an associate editor for Blood and the Journal of Clinical Investigation, respectively.
Her laboratory studies hematopoiesis and myelopoiesis and how mutations in splicing factors and perturbations in RNA modifications contribute to hematologic malignancies such as myelodysplasia and leukemia. Dr. Halene, in collaboration with the Flavell laboratory, has developed the first efficient xenotransplantation model in humanized mice to study myelodysplasia and enable testing of novel drug treatments. Dr. Halene’s research has garnered significant attention from the international community, as evidenced by numerous invited speaking engagements, an invitation to serve as a section editor on myeloid malignancies for a major journal, and publications in top tier journals in her field. In 2015, she was presented with the Sir William Osler Young Investigator Award and in 2019 she was elected a member of the Interurban Clinical Club.

Dr. Halene is Director of the DeLuca Center for Innovation in Hematology Research at Yale Cancer Center. Through generous funding from The Frederick A. DeLuca Foundation, the center has established a comprehensive biospecimen bank and awarded pilot and career development grant funding to advance cutting-edge discoveries in hematologic malignancies and classical hematologic disorders.

**Suchitra Krishnan-Sarin, PhD**, an internationally renowned authority on youth tobacco use and a member of Yale Cancer Center’s Cancer Prevention and Control Research Program, was appointed the **Albert E. Kent Professor of Psychiatry**. Her research seeks to understand the bio-behavioral underpinnings of tobacco and alcohol behaviors among youth and adults, and to develop optimal interventions and regulations to reduce these behaviors.
Dr. Krishnan-Sarin co-leads the Yale Tobacco Center Of Regulatory Science, an NIH-FDA-funded center focused on understanding the role of flavors and other constituents of tobacco products on addiction among youth and adults. She also leads the Yale ENACT (End Nicotine Addiction in Children and Teens) initiative; an American Heart Association-funded center focused on developing interventions for e-cigarette use among youth. She received her PhD in Pharmacology and Toxicology from Purdue University. At Yale she serves as a chair of the Human Investigations Committee (IRB). She is the past President and a current Board member of the Society for Research on Nicotine and Tobacco, a global professional society dedicated to the generation and dissemination of knowledge related to tobacco and nicotine.

Dr. Krishnan-Sarin has participated in U.S. Congressional and NIH briefings on the need for regulations and interventions to prevent youth tobacco use, and has been invited to serve on committees within the American Heart Association, American Academy of Pediatrics and American Association for Cancer Research to work on similar initiatives. She has contributed to multiple U.S. Surgeon General’s reports on tobacco use behaviors and served as a member of the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee. She also serves as a consultant on tobacco regulatory efforts to the Food and Drug Administration, the World Health Organization, Health Canada and other international federal health agencies. She is a current member of the U.S. Centers for Disease Control and Prevention’s Interagency Committee on Smoking and Health.

David Rimm, MD, PhD, was appointed the Anthony N. Brady Professor of Pathology. Dr. Rimm earned his MD and PhD degrees at Johns Hopkins University Medical School followed by a pathology residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is board certified in anatomic pathology and cytopathology.

At Yale since 1994, Dr. Rimm is the director of Yale Pathology Tissue Services and specializes in tissue biomarker assessment in cancer. He also serves as the Director of Translational Pathology and the Director of the
Pathology and the Director of the Physician Scientist Training program in Pathology. His lab group focuses on quantitative pathology using the AQUA® technology invented in his lab, and other quantitative approaches with projects related to predicting response to therapy or recurrence in breast and lung cancer and melanoma and head and neck squamous cell carcinoma. The lab also works on issues related to biospecimen science, especially assay standardization. For discovery of new biomarkers, the lab uses high-plex technologies, including imaging mass cytometry and digital spatial profiling. The work is supported by grants from the National Institutes of Health, the Breast Cancer Research Foundation, and sponsored research agreements from biotech and pharma.

Dr. Rimm serves on the Immunohistochemistry committee for the College of American Pathologists (CAP), the AJCC 9th Edition Panel for Tumor Staging in Breast Cancer and a number of guideline setting committees. He is an author of over 425 peer-reviewed papers and eight patents with an H-index of 110. He was a scientific co-founder of HistoRx, a digital pathology company.

Notables

Sanjay Aneja, MD, Assistant Professor of Therapeutic Radiology and a member of Yale Cancer Center’s Radiobiology and Radiotherapy Research Program, has received the 2022 William O. Seery Clinical Investigator Grant from the Patterson Trust Foundation. The grant is to support implementation of Dr. Aneja’s research on deep learning derived imaging biomarkers for lung cancer.

Rong Fan, PhD, Professor of Biomedical Engineering and Pathology and a member of Yale Cancer Center’s Signal Transduction Research Program, has been elected as a Fellow of the National Academy of Inventors (NAI). Dr. Fan was one of 164 inventors named 2021 NAI fellows by the organization, which annually recognizes the spirit of innovation in creating outstanding inventions.

Congratulations to our 2022 Lion Heart Grant awardees, Mariya Rozenblit, MD, and Judit Jimenez Sainz, PhD. Dr. Rozenblit, Assistant Professor of Medicine (Medical Oncology) and a member of Yale Cancer Center’s Genetics, Genomics, and Epigenetics Research Program, will research “Epigenetic Age Acceleration as a Predictor of Breast Cancer Risk” and Dr. Jimenez Sainz, Associate Research Scientist in the laboratory of Ryan Jensen, MD, PhD, Professor of Therapeutic Radiology, will study, “DNA repair dysfunction induced by altered BRCA2 localization.”

Our Hematology team just returned from the American Society of Hematology annual meeting in Atlanta, where they presented over 50 abstracts highlighting recent advances in research and care for hematological malignancies and benign hematology. Congratulations to our faculty, trainees, and staff of their outstanding work!
Anne Chiang, MD, PhD, Professor of Medicine (Medical Oncology), and Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Ensign Professor of Medicine (Medical Oncology) have co-edited and published a new book along with several members of the Center for Thoracic Cancers at Smilow Cancer Hospital and Yale Cancer Center, *Lung Cancer: New Understandings and Therapies*.

Nancy Ruddle, PhD, John Rodman Paul Professor Emerita of Epidemiology at Yale School of Public Health and a member of Yale Cancer Center’s Cancer Immunology Research Program, has been named a 2022 Distinguished Fellow of the American Association of Immunologists (AAI). The honor recognizes active, long-term AAI members (25 or more years) who have demonstrated one or more of the following: excellence in research accomplishment in the field of immunology; exceptional leadership to the immunology community in academia, foundations, nonprofits, industry, or government at a national or international level; and notable distinction as an educator.

The Cancer Immunology Research Program welcomes Stacy Malaker, PhD, Assistant Professor of Chemistry. Dr. Malaker’s research focus is on developing technologies to identify mucin-domain glycoproteins in cancer. Her expertise is unique to the Cancer Immunology Program and will enable study of the cancer mucinome as immune checkpoints and targets for cell therapy and antibody therapeutics.

Jamie Tam, PhD, MPH, Assistant Professor of Public Health (Health Policy), recently joined the Cancer Prevention and Control Research Program. Dr. Tam’s main area of research focuses on the use of epidemiological and simulation modeling methods to examine smoking-related mortality among people with mental health conditions. Dr. Tam’s work analyzes and compares the relative health gains across different smoking cessation treatment intervention strategies for patients with major depression. Another area of her research aims to clarify the relationship between cigarettes and non-cigarette tobacco products in the context of a rapidly evolving tobacco product landscape. Dr. Tam is an expert in tobacco use disparities and she is co-authoring two forthcoming Surgeon General Reports with the Centers for Disease Control.

Diversity, Equity, and Inclusion

Thank you both for your decades of care and dedication.

The Connecticut Lions Eye Research Foundation, Inc., based in Watertown, CT, has provided a donation of $133,000 to Dr. Renelle Lim, Director of the Ocular Oncology Program at Smilow Cancer Hospital, to continue her clinical research into uveal melanoma. This is the second year of funding from the Foundation for Dr. Lim’s work; they provided support in 2020, as well. Dr. Lim’s goals to use innovative modalities for early detection of uveal melanoma, to treat the cancer at a molecular level to prevent spread or eye removal, and to achieve better survival rates, will advance through her work on this project. The continuing philanthropic support of the Connecticut Lions Eye Research Foundation, Inc. will be instrumental in this effort and we are appreciative for their continued support.
Diversity, Equity, and Inclusion

New DEI Curriculum for Medical Oncology-Hematology Fellowship Program

To facilitate broader discussions on disparities in medicine, Chief Fellows Dr. Anna Kress and Dr. Benjamin Lu, have created Yale’s first Diversity, Equity, and Inclusion (DEI) curriculum as part of the Yale Medical Oncology-Hematology Fellowship Program. To date, they have organized three sessions focused on discussion and trainings related to DEI topics important to the fellows. These are held as part of the didactic component of their fellowship training.

During the first session, Dr. Pamela Kunz, Vice Chief of Diversity, Equity, and Inclusion for Medical Oncology, shared her story and held an open discussion on gender equity in the workplace. The second session was a DEI-focused Journal Club co-led by Dr. Darin Latimore, Yale School of Medicine’s inaugural Deputy Dean for Diversity and Inclusion and Chief Diversity Officer. In attendance were Dr. Barbara Burtness, Interim Associate Cancer Center Director for Diversity, Equity, and Inclusion and Dr. Iris Isufi, Vice Chief of Diversity, Equity and Inclusion for Hematology and they discussed articles focused on misogyny and racism. For the third session, the fellows invited The Women’s Place from The Ohio State University for an interactive, skills-based training session.

In the future, they hope to create spaces for different aspects of DEI and expand the format based on feedback from fellows. Dr. Kress commented that these discussions were already happening organically between fellows, but there was no formal outlet in place. Their goal was to create a forum to cater these discussions and help build skills in the professional and clinical setting. For, as Dr. Lu remarked, “The more diverse and the more open-minded we are as physicians, the better the care we can deliver to all of our patients.”

For more information, please contact Dr. Lu or Dr. Kress.

Employee Profile: Arlene Mingione

As a Practice Nurse in the Smilow Cancer Hospital Care

Sylvia Lempit, APRN with the Smilow Liver Cancer Program, is a rare gem according to Dr. Mario Strazzabosco, Professor of Medicine and Clinical Program Leader of the Liver Cancer Program. “Sylvia specializes in liver disease, liver cancer, and liver transplant, which is a unique combination that you don’t find everywhere.”

“Patients with liver disease run the gamut, and I have pretty much seen it all,” said Sylvia. “Once therapy to treat their cancer is no longer recommended, I continue to monitor liver function and provide interventions and resources to keep them as stable as possible for as long as possible. Patients and their families are so appreciative of this extra support we provide.”

Congratulations to Eric Song, a sixth-year MD/PhD student in the laboratory of Akiko Iwasaki, PhD, Waldemar Von Zedtwitz Professor of Immunobiology, on his selection to this year’s STAT Wunderkinds cohort! STAT Wunderkinds celebrates early-career researchers. Eric has been actively engaged
Smilow Cancer Hospital Care Center in Guilford, Arlene Mingione primarily works with Dr. Su Hsien Lim and Dr. Elan Gorshein. Although she is not interacting directly with patients every day, except by phone, she has found great value in her role as a practice nurse, one family at a time.

After losing her husband to cancer 13 years ago, Arlene felt compelled to volunteer and started on NP-14 while taking pre-rcs for nursing and becoming CNA certified. Eight years ago she transitioned to a role as staff nurse on NP-14 and then as an infusion nurse in Women’s Services on NP-1 for two years while getting her BSN. She is currently working towards her MSN in management and leadership. On a day-to-day basis, Arlene provides education and coordinates care for patients receiving oral chemotherapy, while also assisting with symptom management and transition of care, all by phone and EPIC communications.

“Much of my day is spent at my computer, in what I lovingly call my ‘She-shed,’ and although I miss the eye to eye and soul to soul connection with patients, I have found joy in helping my patients by ensuring they have what they need, especially complex patients who are very sick and may need help navigating care,” said Arlene. Every day brings new challenges, yet Arlene is ready to meet them as an advocate for her patients.

Arlene was recently awarded one of the 2021 Smilow Cares RN/PCA/ACA Scholarships, supported by The Frederick A. DeLuca Foundation that are awarded to those that embrace the mission and vision of Smilow Cancer Hospital, while demonstrating a commitment to oncology nursing, patient care, and to life-long learning. She is also on the executive board of Central Connecticut Oncology Nursing Society, and two quality initiative committees. While working on NP-14, Arlene developed the Nurse Float Survival Guide with a goal to alleviate anxiety for nurses when floating to an unfamiliar floor.

Dr. Gorshein commented, “Arlene is arguably one of the hardest working, thorough, and diligent colleagues I have ever worked with. She consistently goes above and beyond for patient care.”

Recent Publications

Methylation-based Cell-free DNA Signature for Early Detection of Pancreatic Cancer.
**Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis.** 
*Gastroenterology, S0016-5085(21)03797-5.*

**Residual Cancer Burden After Neoadjuvant Chemotherapy And Long-Term Survival Outcomes In Breast Cancer: A Multicentre Pooled Analysis Of 5161 Patients**  
*Lancet Oncology,* Online ahead of print.

Han G, Schell MJ, Reisenbichler ES, Guo B, Rimm DL.  
**Determination of the Number of Observers Needed Tto Evaluate a Subjective Test and its Application in Two PD-L1 Studies**  
*Statistics in Medicine,* Online ahead of print.

Hyder F, Khan MH.  
**Dysregulated Proton and Sodium Gradients Highlight Cancer Invasion and Proliferation**  
*Translational Oncology,* Online ahead of print.

**Optimal Outcome Measures for Assessing Exercise and Rehabilitation Approaches in Chemotherapy-induced Peripheral-neurotoxicity: Systematic Review and Consensus Expert Opinion**  

**Colorectal Cancer Survivorship Care Plans: Variations in Documentation and posttreatment surveillance recommendations**  
*Journal of Surgical Oncology,* Online ahead of print.

Dr. Henry Park, Smilow Cancer Hospital radiation oncologist, shares his insight on advances in the field and patient care in this new video. "I think radiation oncology has improved substantially in the past 10 years in its accuracy & precision, with imaging as well as the delivery of radiation therapy," Dr. Park explains.

Avelumab Maintenance in Advanced Urothelial Carcinoma: Biomarker Analysis of the Phase 3 JAVELIN Bladder 100 Trial
Nature Medicine, Online ahead of print.
Read More

Lustberg MB, Loprinzi CL, Streicher L.
A Pill for Sexual Desire in Female Cancer Survivors: Too Good to be True?
Journal of Clinical Oncology, Online ahead of print.
Read More

Shah N, Krishnamurti L.
Evidence-based Minireview: In Young Children with Severe Sickle Cell Disease, do the Benefits of HLA-identical sibling donor HCT Outweigh the Risks?
Read More

Cheraghlo S, Ugwu N, Girardi M.
Sentinel Lymph Note Biopsy Positivity in Patients with Acral Lentiginous and Other Subtypes of Cutaneous Melanoma
JAMA Dermatology, Online ahead of print.
Read More

Read More

Grant A, Xicola RM, Nguyen V, Lim J, Thorne C, Salhia B, Llor X, Ellis N, Padi M.
Molecular Drivers of Tumor Progression in Microsatellite Stable APC Mutation-negative Colorectal Cancers
Read More

Phase 1/2 Study of Intratumoral F100 (TLR4 agonist) with or without Pembrolizumab in Follicular Lymphoma
Leukemia & Lymphoma, Online ahead of print.
Read More

Weiss SA, Kluger H.
CheckMate-067: Raising the Bar for the Next Decade in Oncology
Journal of Clinical Oncology, Online ahead of print.
Read More

Exciting new phase 2 clinical trial results in @JournalCancer and led by Dr. Alessandro Santin demonstrate need to evaluate & stratify different subtypes of endometrialcancer to make personalized treatment decisions.

Lion Heart, founded by @kathleenvanrijn, supports breastcancer research @YaleCancer and is celebrating their 15th Anniv. and 10th series of research grants! @MariyaRozenblit and @Jujisa are awardees for 2022!

Congratulations to Giulia Biancon @BianconGiulia, Dr. Yimeng Gao @Dr_Yimeng & Dr. Wei Liu, recipients of prestigious 2021 #ASH21 Abstract Achievement Awards!

Dr. Natalia Neparidze .@NataliaNeparid1 and Dr. Scott Huntington @sfhYale report at #ASH21 on changes in multiple myeloma treatment patterns during the start of the COVID19 pandemic.

At #ASH21, Drs. Lai Chan & Markus Müschen @Muschenlab highlight vulnerability n/RAS-driven B-cell acute lymphoblastic leukemia #B-ALL cells that can be leveraged to overcome drug-resistance in refractory B-ALL.

Thank you for your generous support of our patients @SmilowCancer @YaleCancer!

New research presented by Dr. Daria Madeeva & Dr. Alexander Pine @BenignHeme at #ASH21 reveals clues to help treat patients with COVID19 related blood clots.

Reporting right now at #ASH21, @GeorgeGoshuaMD discusses the cost-effectiveness of second-line therapies in adult patients with chronic immune thrombocytopenia.

Join .@Dr_RoryShallis moderate an important overview session on acute myeloid leukemia #AML today at 2:45pm at #ASH21.

Funding and Award Opportunities

Alex’s Lemonade Stand Foundation (ALSF) and RUNX1 Early Career Investigator Grant
The purpose of this grant is to promote the establishment of a new generation of translational and clinical researchers interested in tackling inherited hematologic malignancy predisposition disorders with a focus on RUNX1-familial platelet disorder.
Application Deadline: December 20, 2021

Coordinating Center for HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network (U24)
Through this FOA, the NCI solicits applications from institutions/organizations to participate in the Clinical Sites for HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network. The ‘CASCADE’ Network will conduct pragmatic clinical trials evaluating the effectiveness of clinically proven interventions to overcome barriers and reduce failures in the cervical cancer screening, management, and precancer treatment cascade for women living with HIV.
Application Deadline: December 28, 2021

Research Bases for HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network (UG1)
As an integral part of this Cooperative Agreement-funded network, this FOA will (i) provide scientific and statistical leadership for developing network clinical trials concepts and protocols, overseeing their conduct, and analyzing and publishing their results, (ii) ensure compliance with human research participant protection and other regulatory and administrative reporting requirements, and (iii) work towards creating opportunities for training emerging investigators.
Application Deadline: December 28, 2021

Clinical Sites for HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network (UG1)
As an integral part of this Cooperative Agreement-funded network, this FOA will provide a pluripotent infrastructure for accruing participants to network clinical trials, interface with the UG1 Research Bases and U24 Network Coordinating Center during concept and protocol development to provide insights and input on clinical significance and study feasibility and provide on-site operational leadership for the successful conduct of the network clinical trials.

Calendar

Yale Liver Update
December 17; 1:00 PM
Joseph Lim, MD | David N. Assis, MD | Guadalupe Garcia-Tsao, MD, FRCP | Simona Jakab, MD | Wajahat Mehal, PhD, MD, BA | Tamar Taddei, MD | Pramod Mistry, MBBS, PhD, MA, MD
Learn More

Yale CCEH Rising Stars in Hematology Series
December 17; 1:00 PM
Anatomy of Hematopoiesis in the Bone Marrow
Daniel Lucas, PhD
Learn More

Yale Cancer Answers
Yale Cancer Center (YCC) K12 Calabresi Immuno-Oncology Training Program Scholar Awards
We are pleased to solicit applications for the Yale Cancer Center (YCC) K12 Calabresi Immuno-Oncology Training Program (IOTP) Scholar Award for junior faculty to enhance research skills beyond the training provided during graduate and postgraduate training.

**Application Deadline:** January 3, 2022

YCC Cancer Microbiome Pilot Grants
Thanks to the generosity of a private donor, YCC seeks to fund early-stage laboratory investigations that will advance our understanding of the host microbiome and microbial niches in cancer progression and therapy. Cancer associated microorganisms include bacteria, viruses, fungi, and parasites.

**Application Deadline:** January 3, 2021

Mary Kay Ash Foundation Cancer Research Grant
This grant focuses on funding research for innovative grants for translational research of cancers affecting women (ovarian, uterine, breast, endometrial or cervical cancer among others).

**Internal Deadline:** January 3, 2021

Brain Research Foundation: Brain Research Foundation Seed Grant Program 2022
The objective of the BRF Seed Grant Program is to support new and innovative projects, especially those of junior faculty, who are working in new research directions. BRF Seed Grant awards are not intended to supplement existing grants.

**Application Deadline:** January 4, 2021

AACR Cancer Disparities Research Fellowships
These represent an effort to encourage and support postdoctoral or clinical research fellows to conduct cancer disparities research and to establish a successful career path in this field. The research proposed for funding may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to cancer disparities.

**Application Deadline:** January 7, 2022

CDA for Inclusion and Diversity in Breast Cancer Research
Designed with the primary goal of increasing diversity in the oncology workforce and cancer research. This CDA will provide funding to clinical investigators who have received their initial faculty appointment and identify as members of racial and/or ethnic groups traditionally excluded in academic medicine and biomedical research.

**Application Deadline:** January 10, 2022

Share your news!
Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette
Director, Public Affairs and Communications
YIA for Diversity and Inclusion in Breast Cancer Research
Provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this grant is to fund physicians during the transition from a fellowship program to a faculty appointment.

Application Deadline: January 10, 2022
Read More

HESI THRIVE
THRIVE, a partner in the 2018 Biden Cancer Initiative, provides seed grants for nonclinical, clinical, and translational research and technology-based solutions that enhance our ability to predict when and how adverse effects may occur in patients who have received cancer treatment. THRIVE also supports the development of approaches to avoid or lessen these effects.

Letter of Intent Due: January 10, 2022
Read More

Bladder Cancer Research Innovation Awards
This award supports experienced investigators with exceptionally novel and creative projects designed to produce significant advances in our understanding of the management of bladder cancer. The proposed research may be basic, translational, clinical or epidemiological and must have direct applicability and relevance to bladder cancer. Applications must include innovative approaches and new ideas to be eligible for funding.

Application Deadline: January 12, 2022
Read More

Susan D. Flynn Oncology Nursing Fellowship at Smilow Cancer Hospital
The Susan D. Flynn Oncology Nursing Fellowship Program at Smilow Cancer Hospital is intended to help stimulate the career interest and foster the professional development of future oncology nurses. Since 2014, Greenwich Hospital has been home to the Fellowship, but this year the program will be expanded to Smilow Cancer Hospital in New Haven as well. Six undergraduate nursing students enrolled in a BSN program who have just completed their junior year will be chosen for an immersive 8-week experience in oncology nursing; two at Greenwich Hospital and four in New Haven.

The fellowship will enhance the student’s core clinical education through direct observation and exposure to oncology nursing care. Through this experience, students will learn about the various oncology nursing roles and responsibilities and discover possible career opportunities.

Application Deadline: January 14, 2022. Applications should be sent to: kristina.capretti@greenwichhospital.org
http://sdfondp.com/

The Jackson Laboratory – Yale Cancer Center Joint Pilot Project Grant: Deciphering the Tumor Microenvironment Using Advanced Imaging and Analysis
The pilot funding will support innovative cancer research on the topic of “Deciphering the Tumor Microenvironment Using Advanced Imaging and Analysis.” Proposals may be focused on spatial data analysis, technology investigation, or hypothesis-based research making innovative use of advanced imaging techniques.

Proposals are due by: January 14, 2022. Email your application to jaxccadmin@jax.org
**BMSF Diversity in Clinical Trials Career Development Program**
The intent of this program is to increase diversity in clinical trials. The initiative is comprised of a Career Development Program for early-stage clinical investigators and a Clinical Investigator Pipeline Program (BMSF CIPP) for rising second-year medical students.

**Application Deadline:** January 14, 2022

**ASCO Medical Student Rotation for Underrepresented Populations**
Provides financial support for U.S. medical students from populations underrepresented in medicine and who are interested in oncology as a career to experience a minimum 4-week clinical or clinical research rotation.

**Application Deadline:** January 25, 2022

**ASCO Diversity Mentoring Program**
Designed to encourage U.S. based medical students and residents who are underrepresented in medicine to pursue rewarding careers in oncology by pairing with a mentor.

**Application Deadline:** January 25, 2022

**BMSF Clinical Investigator Pipeline Program**
This Program was established to build the pipeline of community oriented clinical trialists of diverse backgrounds who are committed to increasing diversity, equity and inclusion in clinical trials. This will be a 6-week summer externship program for 250 underrepresented medical students, and with hands-on community-oriented clinical trial experience in underserved communities.

**Application Deadline:** January 28th, 2022

**Leslie Warner Postdoctoral Fellowships for Cancer Research**
The Fellowships will support early-stage promising trainees that are conducting innovative basic, translational, clinical, or population-based cancer research with a Yale Cancer Center member. Relevance of proposed research to our catchment area priorities is also encouraged. Candidates may have up to one year of postdoctoral experience from the time of application.

**Internal Deadline:** February 1, 2022

**Leukemia Research Foundation Grant**
The application process for the 2022-2023 funding cycle has begun! Grants of up to $100K are available to new investigators -- researchers within seven years of their first independent faculty-level position. Research projects must focus on a blood cancer (leukemia, lymphoma, myeloma, or MDS).

**Letter of Intent Due:** February 4, 2022

**Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01, R21)**
The purpose of this FOA is to support research that elucidates
The purpose of this FOA is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies.

**Application Deadline:** February 5, 2022

Read More

**Early K99/R00 Funding Opportunity Announcements**

The NCI just reissued “early K99/R00” - NCI Pathway to Independence Award for Outstanding Early-Stage Postdoctoral Researchers FOAs that might be of interest to some postdoctoral fellows.

- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)

**Application Deadlines:** February 28, 2022

Read More

**NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00)**

The purpose of this award is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions.

**Application Deadline:** February 28, 2022

Read More

**NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)**

This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

**Application Deadline:** February 28, 2022

Read More

**DeLuca Career Development Award 2022**

The purpose of this career development award is to provide early career clinical or laboratory-based investigators in Hematology, the opportunity to focus on research to advance patient care, therapies, and outcomes and with the ultimate goal to achieve independent support for their research from a national agency. For further information contact Richard.Carr@yale.edu

Letter of Intent Due: March 1, 2022
Letter of Intent Due: March 1, 2022
Read More